1. Home
  2. SDOT vs GRI Comparison

SDOT vs GRI Comparison

Compare SDOT & GRI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Sadot Group Inc.

SDOT

Sadot Group Inc.

HOLD

Current Price

$1.56

Market Cap

3.1M

ML Signal

HOLD

Logo GRI Bio Inc.

GRI

GRI Bio Inc.

HOLD

Current Price

$2.45

Market Cap

3.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SDOT
GRI
Founded
2014
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Restaurants
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.1M
3.3M
IPO Year
2019
2020

Fundamental Metrics

Financial Performance
Metric
SDOT
GRI
Price
$1.56
$2.45
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$160.00
AVG Volume (30 Days)
9.2K
68.2K
Earning Date
05-13-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
490.91
N/A
EPS
N/A
N/A
Revenue
$7,929,137.00
N/A
Revenue This Year
$12.76
N/A
Revenue Next Year
$5.54
N/A
P/E Ratio
N/A
N/A
Revenue Growth
60.08
N/A
52 Week Low
$0.72
$0.18
52 Week High
$13.02
$6.70

Technical Indicators

Market Signals
Indicator
SDOT
GRI
Relative Strength Index (RSI) 34.26 50.98
Support Level $1.26 $2.16
Resistance Level $2.31 $2.66
Average True Range (ATR) 0.12 0.20
MACD 0.02 0.01
Stochastic Oscillator 37.40 48.48

Price Performance

Historical Comparison
SDOT
GRI

About SDOT Sadot Group Inc.

Sadot Group Inc operates in the food supply chain sector, connecting producers and consumers across the globe, delivering agri-commodities from producing geographies such as the Americas, Africa, and the Black Sea to consumer markets in Southeast Asia, China and the Middle East/North Africa (MENA) region. Its reportable segment includes Sadot food service and Sadot agri-foods. The key revenue is coming from the Sadot agri-foods segment which engaged in farming, commodity trading, and shipping of food and feed.

About GRI GRI Bio Inc.

GRI Bio Inc is a clinical-stage biotech company focused on discovering, developing, and commercializing therapies targeting serious diseases associated with dysregulated immune responses that to inflammatory, fibrotic, and autoimmune disorders. GRI Bio's program, GRI-0621, is a small molecule RAR-beta and gamma dual agonist that inhibits the activity of human NKT I cells, returning the immune system to homeostasis. It is also an oral formulation of tazarotene, a synthetic RAR-beta and gamma selective agonist for the topical treatment of psoriasis and acne. The company's other product candidate GRI-0803 is a novel oral agonist of type 2 Natural Killer T (type 2 NKT) cells which can be a potential treatment for autoimmune disorders.

Share on Social Networks: